Inhibikase Therapeutics I... (IKT)
Inhibikase Therapeutics Statistics
Share Statistics
Inhibikase Therapeutics has 74.34M shares outstanding. The number of shares has increased by 861.21% in one year.
| Shares Outstanding | 74.34M |
| Shares Change (YoY) | 861.21% |
| Shares Change (QoQ) | 3.23% |
| Owned by Institutions (%) | 0.05% |
| Shares Floating | 45.53M |
| Failed to Deliver (FTD) Shares | 11 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 1.32M, so 1.81% of the outstanding shares have been sold short.
| Short Interest | 1.32M |
| Short % of Shares Out | 1.81% |
| Short % of Float | 2.24% |
| Short Ratio (days to cover) | 10.05 |
Valuation Ratios
The PE ratio is -2.8 and the forward PE ratio is -2.75. Inhibikase Therapeutics's PEG ratio is 0.04.
| PE Ratio | -2.8 |
| Forward PE | -2.75 |
| PS Ratio | 0 |
| Forward PS | 0.9 |
| PB Ratio | 0.81 |
| P/FCF Ratio | -4.02 |
| PEG Ratio | 0.04 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Inhibikase Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 26.37, with a Debt / Equity ratio of 0.
| Current Ratio | 26.37 |
| Quick Ratio | 26.37 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.83M |
| Employee Count | 15 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -9.52% in the last 52 weeks. The beta is 1.02, so Inhibikase Therapeutics's price volatility has been higher than the market average.
| Beta | 1.02 |
| 52-Week Price Change | -9.52% |
| 50-Day Moving Average | 2.25 |
| 200-Day Moving Average | 2.1 |
| Relative Strength Index (RSI) | 42.83 |
| Average Volume (20 Days) | 176.16K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -28.59M |
| Net Income | -27.52M |
| EBITDA | -28.59M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.16 |
Balance Sheet
The company has 56.49M in cash and 110.52K in debt, giving a net cash position of 56.38M.
| Cash & Cash Equivalents | 56.49M |
| Total Debt | 110.52K |
| Net Cash | 56.38M |
| Retained Earnings | -94.42M |
| Total Assets | 98.6M |
| Working Capital | 94.72M |
Cash Flow
In the last 12 months, operating cash flow was -19.15M and capital expenditures 0, giving a free cash flow of -19.15M.
| Operating Cash Flow | -19.15M |
| Capital Expenditures | 0 |
| Free Cash Flow | -19.15M |
| FCF Per Share | -0.81 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IKT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for IKT is $8, which is 321.1% higher than the current price. The consensus rating is "Hold".
| Price Target | $8 |
| Price Target Difference | 321.1% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jun 30, 2023. It was a backward split with a ratio of 1:6.
| Last Split Date | Jun 30, 2023 |
| Split Type | backward |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | 22.75 |
| Piotroski F-Score | 2 |